Disease · MONDO_0007915
Comparisons in its trials125
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 125
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Benlysta vs Non-Benlysta: deaths from any cause | 48 of 1,924 | 29 of 881 | 2,805 | NCT01729455 | Trial comparisons |
| Benlysta vs Non-Benlysta: serious adverse events | 248 of 1,924 | 108 of 881 | 2,805 | NCT01729455 | Trial comparisons |
| Belimumab 10 mg/kg (DB Phase) vs Placebo (DB Phase): Number of Participants With Severe AEs [DB Phase] | 46 of 331 | 37 of 165 | 496 | NCT01632241 | Trial comparisons |
| Belimumab 10 mg/kg (DB Phase) vs Placebo (DB Phase): Number of Participants With AEs Leading to Treatment Discontinuation [DB Phase] | 22 of 331 | 12 of 165 | 496 | NCT01632241 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements | 45 of 180 | 45 of 182 | 362 | NCT02446899 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests | 72 of 180 | 87 of 182 | 362 | NCT02446899 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants With One or More Adverse Events (AEs) | 162 of 180 | 154 of 182 | 362 | NCT02446899 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 | 86 of 180 | 57 of 182 | 362 | NCT02446899 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants With One or More Adverse Events of Special Interest (AESIs) | 29 of 180 | 20 of 182 | 362 | NCT02446899 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: deaths from any cause | 1 of 180 | 0 of 182 | 362 | NCT02446899 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: serious adverse events | 16 of 180 | 34 of 182 | 362 | NCT02446899 | Trial comparisons |
| Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) vs Placebo to Belimumab 10 mg/kg (OL Phase): Number of Participants With Severe AEs [OL Phase] | 9 of 242 | 10 of 117 | 359 | NCT01632241 | Trial comparisons |
| Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) vs Placebo to Belimumab 10 mg/kg (OL Phase): Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase] | 0 of 242 | 1 of 117 | 359 | NCT01632241 | Trial comparisons |
| PBO+SOC vs DZP+SOC: deaths from any cause | 0 of 108 | 1 of 213 | 321 | NCT04294667 | Trial comparisons |
| PBO+SOC vs DZP+SOC: serious adverse events | 16 of 108 | 21 of 213 | 321 | NCT04294667 | Trial comparisons |
| Anifrolumab 300 mg vs Placebo: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group | 72 of 150 | 46 of 151 | 301 | NCT02446899 | Trial comparisons |
| Rituximab 1000 mg + Prednisone vs Placebo + Prednisone: Number of Participants Who Achieved a PCR (Including MCR) | 50 of 169 | 25 of 88 | 257 | NCT00137969 | Trial comparisons |
| Rituximab 1000 mg + Prednisone vs Placebo + Prednisone: Number of Participants Who Achieved an MCR in The ITT Population | 14 of 169 | 9 of 88 | 257 | NCT00137969 | Trial comparisons |
| Rituximab 1000 mg + Prednisone vs Placebo + Prednisone: Number of Participants Who Achieved an MCR (Excluding PCR) | 21 of 169 | 14 of 88 | 257 | NCT00137969 | Trial comparisons |
| Rituximab 1000 mg + Prednisone vs Placebo + Prednisone: Number of Participants Who Achieved a BILAG C or Better in All Domains | 42 of 169 | 24 of 88 | 257 | NCT00137969 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007915/comparisons